ts-121
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02448212)
Timeline
Indications
Mechanism of action
- Vasopressin V1b receptorANTAGONIST
AVPR1B antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ts-121
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03093025 | Phase 2 | Jul 1, 2017 | Taisho Pharmaceutical |
| NCT02448212 | Phase 1 | May 1, 2015 | Taisho Pharmaceutical, Yale University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taisho Pharmaceutical | For profit | 2 | 2 | 2 | 2015 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1